Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
FREDERICK, Md., April 27, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions, saw strong interest in...
-
Austin, United States, April 27, 2026 (GLOBE NEWSWIRE) -- According to SNS Insider, The Respiratory Syncytial Virus Vaccines Market size valued at USD 3.48 billion in 2025 and is projected to...
-
Sanofi place 2,3 milliard d’euros d’emprunts obligataires Paris, 24 avril 2026 - Sanofi annonce avoir placé avec succès une émission obligataire en 3 tranches (les « obligations ») pour un montant...
-
Sanofi successfully prices 2.3 billion of bond issue Paris, April 24, 2026 - Sanofi announces that it has successfully priced its offering of €2.3 billion of notes across 3 tranches: €1,000...
-
Dublin, April 24, 2026 (GLOBE NEWSWIRE) -- The "Germany Anemia Treatment Market Report by Disease Type, Therapy Class, Route of Administration, Cities and Company Analysis, 2026-2034" has been added...
-
Cenrifki de Sanofi (tolebrutinib) recommandé par le Comité des médicaments à usage humain (CMUH) pour être approuvé par l’UE pour le traitement de la sclérose en plaques secondairement progressive...
-
Sanofi’s Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses Recommendation based on the HERCULES phase 3 study which...
-
PARIS, April 24, 2026 (GLOBE NEWSWIRE) -- SANOFI Pre Stabilisation Notice HSBC (contact: syndexecution@noexternalmail.hsbc.com) hereby gives notice, as Stabilisation Coordinator, that the...
-
Regeneron will provide Otarmeni™ (lunsotogene parvec-cwha), its recently approved gene therapy for an ultra-rare form of genetic hearing loss, for free in the U.S. Regeneron will lower Medicaid...
-
New York, USA, April 23, 2026 (GLOBE NEWSWIRE) -- Chronic Obstructive Pulmonary Disease Clinical Trial Landscape Expands: Over 65 Companies Advancing Next-Generation Therapies | DelveInsight The...